Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
REGULATED INFORMATION
GHENT, Belgium, 21 April 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 57,125 common shares have been issued by the Company in exchange for €398,801.77 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has 61,133,199 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,388,305 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Lies Vanneste
Director IR
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations: FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/633cfd55-8e30-43b9-bbf3-e4dd9400e3c6
